Results 21 to 30 of about 125,339 (239)

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty [PDF]

, 2013
Rapid degradation of glucagon-like peptide-1 (GLP-1) by dipeptidyl peptidase-4 suggests that endogenous GLP-1 may act locally before being degraded. Signaling via the vagus nerve was investigated in 20 truncally vagotomized subjects with pyloroplasty and
Deacon, Carolyn F., Hartmann, Bolette, Holst, Jens Juul, Hovendal, Claus, Knop, Filip Krag, Meisner, Søren, Plamboeck, Astrid, Svendsen, Lars Bo, Veedfald, Simon, Vilsbøll, Tina, Wettergren, André   +10 more
core   +1 more source

Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies. [PDF]

, 2016
BACKGROUND: Glucagon-like peptide-1 (7-36) amide (GLP-1) protects against stunning and cumulative left ventricular dysfunction in humans. The mechanism remains uncertain but GLP-1 may act by opening mitochondrial K-ATP channels in a similar fashion to ...
Axell, Richard G, Brown, Adam J, Clarke, Sophie J, Dutka, David P, Giblett, Joel P, Hoole, Stephen P, McCormick, Liam, O'Sullivan, Michael, Read, Philip A, Reinhold, Johannes, West, Nick EJ, White, Paul A   +11 more
core   +4 more sources

Molecular regulation of hormone secretion, growth and apoptosis of GLP-1-producing cells [PDF]

, 2013
Type 2 diabetes (T2D) spreads like an epidemic in today’s society, and there is a great need for new and improved treatments. T2D is characterized by hyperglycemia, resulting from impaired insulin production and insulin resistance in peripheral ...
Kappe, Camilla
core   +1 more source

GLP‐1 Is a Coronary Artery Vasodilator in Humans

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background The mechanism underlying the beneficial cardiovascular effects of the incretin GLP‐1 (glucagon‐like peptide 1) and its analogues in humans is elusive.
Sophie J. Clarke, Joel P. Giblett, Lucy L. Yang, Annette Hubsch, Tian Zhao, Muhammad Aetesam‐ur‐Rahman, Nick E. J. West, Michael O'Sullivan, Nichola Figg, Martin Bennett, Nicolai J. Wewer Albrechtsen, Carolyn F. Deacon, Joseph Cheriyan, Stephen P. Hoole   +13 more
doaj   +1 more source

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes [PDF]

Electronic Physician, 2013
Background: The aim of this study was to examine the effect of purslane seeds in glucagon-like peptide-1 concentration and glucagon-like peptide-1 receptor in women with diabetes. Methods: This was a quasi-experimental study.
Sara Heidarzadeh, Parvin Farzanegi, Mohammad Ali Azarbayjani, Roja Daliri   +3 more
doaj   +2 more sources

β Cell GLP-1R Signaling Alters α Cell Proglucagon Processing after Vertical Sleeve Gastrectomy in Mice

Cell Reports, 2018
Summary: Bariatric surgery, such as vertical sleeve gastrectomy (VSG), causes high rates of type 2 diabetes remission and remarkable increases in postprandial glucagon-like peptide-1 (GLP-1) secretion.
Darline Garibay, Jon Lou, Seon A. Lee, Karolina E. Zaborska, Margot H. Weissman, Erica Sloma, Leanne Donahue, Andrew D. Miller, Andrew C. White, M. Dodson Michael, Kyle W. Sloop, Bethany P. Cummings   +11 more
doaj   +1 more source

Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model [PDF]

, 2015
Glucagon-like peptide 1 (GLP-1) is a hormone and a growth factor. GLP-1 mimetics are currently on the market as treatments for type 2 diabetes. They also have shown neuroprotective properties in animal models of neurodegenerative disorders.
Chen, YiMei, Holscher, Christian, Li, Lin, Zhang, YanFang   +3 more
core   +1 more source

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation [PDF]

, 2016
The glucagon-like peptide receptor (GLP-1R), which is a G-protein coupled receptor (GPCR), signals through both Gαs and Gαq coupled pathways and ERK phosphorylation to stimulate insulin secretion.
A Bond, A Thompson, A Thompson, A Thompson, A Thompson, AC Hanyaloglu, Aiysha Thompson, B Thorens, BD Green, C Koole, C Montrose-Rafizadeh, C Orskov, CE Groer, CR Underwood, D Wootten, D Wootten, DJ Drucker, FS Willard, FS Willard, GG Holz, JC Davies, JC Davies, Jeffrey W. Stephens, JT Patterson, K Coopman, K Venkateswarlu, K Zahn, KW Sloop, L Ma, LB Knudsen, M Edavalath, ME Doyle, MR Price, N Irwin, N Li, P Vazquez, R Goke, R López de Maturana, Rasheed Ahmad, RL Thomas, RS Kuna, S Takhar, SK Mathi, SN Roed, Stephen C. Bain, T Kim Chung le, TM Bridges, TP Vahl, V Kanamarlapudi, V Serre, Venkateswarlu Kanamarlapudi, WM Nolte, YH Cheong   +52 more
core   +18 more sources

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors

Physiological Reports, 2017
Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone increasing postprandial insulin release. GLP‐1 also induces diuresis and natriuresis in humans and rodents. The GLP‐1 receptor is extensively expressed in the renal vascular tree in normotensive rats
Jonas Ronn, Elisa P. Jensen, Nicolai J. Wewer Albrechtsen, Jens Juul Holst, Charlotte M. Sorensen   +4 more
doaj   +1 more source

Adverse effects of GLP – 1 Receptor Agonists

Journal of Education, Health and Sport
Introduction and purpose Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss.
Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska   +9 more
doaj   +1 more source